Literature DB >> 7695237

Human immunodeficiency virus type 1 tat activates non-N-methyl-D-aspartate excitatory amino acid receptors and causes neurotoxicity.

D S Magnuson1, B E Knudsen, J D Geiger, R M Brownstone, A Nath.   

Abstract

The human immunodeficiency virus type 1 (HIV-1) protein Tat is known to be released from HIV-1-infected cells. We show that micromolar concentrations of Tat depolarized young rat and adult human neurons. In addition, Tat, at similar concentrations, was toxic to human fetal neurons in culture. Tat-induced responses were insensitive to the Na+ channel blocker tetrodotoxin, suggesting a direct effect of Tat on neurons. Tat-induced depolarizations and cytotoxicity were blocked by the excitatory amino acid antagonist kynurenate. The N-methyl-D-aspartate receptor antagonist D-2-amino-5-phosphonovalerate had little effect on Tat-induced depolarizations but did provide protection from Tat neurotoxicity. These results suggest that Tat, released from HIV-1-infected cells, may be an important mediator of neurotoxicity observed in HIV-1 encephalopathy.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7695237     DOI: 10.1002/ana.410370314

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  100 in total

Review 1.  In vitro and animal models of human immunodeficiency virus infection of the central nervous system.

Authors:  Chadd E Nesbit; Stanley A Schwartz
Journal:  Clin Diagn Lab Immunol       Date:  2002-05

2.  Inhibition of Tat-mediated HIV-1 replication and neurotoxicity by novel GSK3-beta inhibitors.

Authors:  Kylene Kehn-Hall; Irene Guendel; Lawrence Carpio; Leandros Skaltsounis; Laurent Meijer; Lena Al-Harthi; Joseph P Steiner; Avindra Nath; Olaf Kutsch; Fatah Kashanchi
Journal:  Virology       Date:  2011-04-22       Impact factor: 3.616

Review 3.  Effects of opiates and HIV proteins on neurons: the role of ferritin heavy chain and a potential for synergism.

Authors:  Lindsay Festa; Olimpia Meucci
Journal:  Curr HIV Res       Date:  2012-07       Impact factor: 1.581

4.  Human immunodeficiency virus tat gene transfer to the murine central nervous system using a replication-defective herpes simplex virus vector stimulates transforming growth factor beta 1 gene expression.

Authors:  S Rasty; P Thatikunta; J Gordon; K Khalili; S Amini; J C Glorioso
Journal:  Proc Natl Acad Sci U S A       Date:  1996-06-11       Impact factor: 11.205

5.  Cell-specific actions of HIV-Tat and morphine on opioid receptor expression in glia.

Authors:  Jadwiga Turchan-Cholewo; Filomena O Dimayuga; Qunxing Ding; Jeffrey N Keller; Kurt F Hauser; Pamela E Knapp; Annadora J Bruce-Keller
Journal:  J Neurosci Res       Date:  2008-07       Impact factor: 4.164

6.  Novel neuroprotective GSK-3β inhibitor restricts Tat-mediated HIV-1 replication.

Authors:  Irene Guendel; Sergey Iordanskiy; Rachel Van Duyne; Kylene Kehn-Hall; Mohammed Saifuddin; Ravi Das; Elizabeth Jaworski; Gavin C Sampey; Svetlana Senina; Leonard Shultz; Aarthi Narayanan; Hao Chen; Benjamin Lepene; Chen Zeng; Fatah Kashanchi
Journal:  J Virol       Date:  2013-11-13       Impact factor: 5.103

Review 7.  Involvement of organelles and inter-organellar signaling in the pathogenesis of HIV-1 associated neurocognitive disorder and Alzheimer's disease.

Authors:  Nabab Khan; Norman J Haughey; Avindra Nath; Jonathan D Geiger
Journal:  Brain Res       Date:  2019-08-16       Impact factor: 3.252

8.  Neurotoxicity of HIV-1 Tat protein: involvement of D1 dopamine receptor.

Authors:  Janelle M Silvers; Marina V Aksenova; Michael Y Aksenov; Charles F Mactutus; Rosemarie M Booze
Journal:  Neurotoxicology       Date:  2007-07-22       Impact factor: 4.294

Review 9.  Benzodiazepines, glia, and HIV-1 neuropathogenesis.

Authors:  J R Lokensgard; C C Chao; G Gekker; S Hu; P K Peterson
Journal:  Mol Neurobiol       Date:  1998-08       Impact factor: 5.590

10.  Neuronal toxicity in HIV CNS disease.

Authors:  Jane Kovalevich; Dianne Langford
Journal:  Future Virol       Date:  2012-07-01       Impact factor: 1.831

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.